Double-blind comparison of amoxapine and imipramine in the treatment of depressed patients.
A 5-week double-blind study compared amoxapine to imipramine (2:1 dosage ratio) in the treatment of depressed outpatients. The two agents were similar in anti-depressant efficacy and rapidity of action. The most common adverse reactions to both drugs were anticholinergic effects and sedation; cardiovascular effects were minimal. A few amoxapine-treated patients developed adverse effects typical of neuroleptic drugs: some experienced extrapyramidal signs, one developed galactorrhea, and most showed elevated plasma prolactin concentrations. Amoxapine was associated with significant neuroleptic activity in plasma. No correlation was found between blood levels of either drug and therapeutic response.
D000293:Adolescent; D000328:Adult; D000553:Ambulatory Care; D000657:Amoxapine / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D001480:Basal Ganglia Diseases / Q000139:chemically induced; D002986:Clinical Trials as Topic; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D003989:Dibenzoxazepines / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D005687:Galactorrhea / Q000139:chemically induced; D006801:Humans; D007099:Imipramine / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011247:Pregnancy; D011388:Prolactin / Q000097:blood; D011569:Psychiatric Status Rating Scales
D003989:Dibenzoxazepines; D011388:Prolactin; D007099:Imipramine; D000657:Amoxapine